Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetaphil is a prominent brand of dermatological skincare products specifically engineered for individuals with sensitive, dry, or compromised skin, including those suffering from conditions like atopic dermatitis and psoriasis. Originally developed in 1947 and currently owned by Galderma, the Cetaphil portfolio encompasses a wide range of cleansers, moisturizers, and sunscreens. The therapeutic efficacy of Cetaphil products, particularly the moisturizers, is derived from a combination of humectants such as glycerin, which attract water into the stratum corneum, and occlusives like petrolatum and dimethicone, which form a physical barrier to prevent transepidermal water loss (TEWL). Many formulations also incorporate skin-soothing agents like panthenol and niacinamide to support skin barrier repair and reduce inflammation. While primarily available over-the-counter, Cetaphil is frequently integrated into clinical treatment regimens as an essential adjunctive therapy to maintain skin integrity and enhance the efficacy of topical pharmacological treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cetaphil.